Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexlansoprazole - Takeda

Drug Profile

Dexlansoprazole - Takeda

Alternative Names: Dexilant; Dexivant; Kapidex™; T-168390; TAK-390; TAK-390 modified release; TAK-390MR; TAK-390MROD

Latest Information Update: 01 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Anti-inflammatories; Antiulcers; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Antacids; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Erosive oesophagitis; Gastro-oesophageal reflux
  • No development reported Gastrointestinal disorders

Most Recent Events

  • 02 Jul 2019 Takeda plans to re-initiate a phase II trial in Erosive oesophagitis (In infants, In children) in USA, Belgium, Israel, Italy, Mexico, Poland, Portugal and Brazil (PO, Capsule) NCT02615184)
  • 01 Jul 2019 Takeda plans to re-initiate a phase II trial in Gastro-oesophageal efflux in Belgium, Brazil, Israel, Italy, Mexico, Poland, Portugal, USA (PO, Capsule) (NCT02616302)
  • 10 Mar 2019 Takeda completes a phase I trial in Healthy volunteers in USA (PO) (NCT03801148)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top